Predicted to enable DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II-specific DNA-binding transcription factor binding activity. Involved in negative regulation of cytosolic calcium ion concentration. Predicted to be located in nucleoplasm. Predicted to be active in nucleus. Orthologous to human GTF2I (general transcription factor IIi); INTERACTS WITH 17alpha-ethynylestradiol; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GTF2I protein
[Clofibrate co-treated with Acetaminophen] affects the expression of GTF2I mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of GTF2I mRNA]
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GTF2I protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GTF2I protein
[cypermethrin co-treated with decamethrin co-treated with fenvalerate co-treated with cyhalothrin co-treated with Allethrins] results in decreased expression of GTF2I protein
[Clofibrate co-treated with Acetaminophen] affects the expression of GTF2I mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of GTF2I mRNA]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2I mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GTF2I mRNA